TAO Synergies EBIT

The latest EBIT for TAOX is $-9B as of June 2026. That compares with $-4.5M in the prior-year period — down 200286.5% year over year. That is below the Healthcare sector average of $99B. Investors often review this figure alongside TAO Synergies's historical trend and sector peers before judging valuation or financial health.

Over the past year, TAOX's EBIT moved from $-4.5M to $-9B — a 200286.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in TAO Synergies's operating scale or balance-sheet position.

Against Healthcare companies, TAOX currently prints $-9B for EBIT, while the sector average sits near $99B. That is roughly 109.1% below the sector mean. Large gaps often invite a closer look at TAO Synergies's growth, margins, and balance sheet.

A EBIT figure of $-9B for TAOX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $99B. Explore the charts below for those layers of context.

After noting TAOX's EBIT ($-9B), review year-over-year change from $-4.5M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.